{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:07:26Z","timestamp":1761844046173},"reference-count":52,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Acute lymphoblastic leukemia (ALL) in adults is a rare disease. The results of therapy remain unsatisfactory, and progress has been relatively slow. This article will focus on curative therapy in patients aged 30 to 60 years, but will also discuss the management of elderly patients with ALL. Recent large trials have increased our knowledge of the factors that determine outcome, and have clarified the role of blood and marrow transplantation in the management of this disease. These trials have also highlighted the major issues we need to focus on if we are to improve outcomes. This article describes the results of chemotherapy and blood and marrow transplantation for Philadelphia chromosome negative and positive adult ALL in the \u201colder\u201d adult patient, but also critically examines the major controversies and suggests how they might be resolved. The role of allografting in adult ALL is comprehensively discussed. Results of recent studies on T-cell ALL and reduced-intensity allografting are reviewed. A better understanding of the biology of the disease (including gene profiling) may allow individualization of therapy and, in time, targeted therapy.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.13","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T14:08:48Z","timestamp":1295186928000},"page":"13-20","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Treating the \u201cOlder\u201d Adult With Acute Lymphoblastic Leukemia"],"prefix":"10.1182","volume":"2010","author":[{"given":"David I.","family":"Marks","sequence":"first","affiliation":[{"name":"Haematology and Stem Cell Transplantation, Bristol BMT Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111716305794600_B1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","article-title":"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993)","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"2019111716305794600_B2","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/ Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B3","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1182\/blood-2007-05-038950","article-title":"How I treat acute lymphoblastic leukaemia","volume":"110","author":"Goldstone","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B4","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2007-12-128918","article-title":"Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission","volume":"112","author":"Marks","year":"2008","journal-title":"Blood"},{"key":"2019111716305794600_B5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1182\/blood.V114.22.872.872","article-title":"Comparison of outcomes for nonmyeloablative and myeloablative conditioning for adults with ALL in first and second complete remission [abstract 872]","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111716305794600_B7","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1182\/blood-2006-09-045351","article-title":"Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511","volume":"109","author":"Wetzler","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B8","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111716305794600_B9","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.hoc.2009.07.005","article-title":"Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia","author":"Thomas","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111716305794600_B11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/pbc.22209","article-title":"A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report","volume":"53","author":"Angiolillo","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"2019111716305794600_B12","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia with hyperCVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"2019111716305794600_B13","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1200\/JCO.2005.03.2177","article-title":"High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group","volume":"24","author":"Yanada","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111716305794600_B14","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2005-11-4386","article-title":"Alternating versus concurrent schedules of imatinib and chemotherapy as front line therapy for Philadelphia positive acute lymphoblastic leukemia","volume":"108","author":"Wassmann","year":"2006","journal-title":"Blood"},{"key":"2019111716305794600_B15","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","article-title":"Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study","volume":"109","author":"De Labarthe","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2009.011221","article-title":"Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial","volume":"95","author":"Ribera","year":"2009","journal-title":"Haematologica"},{"key":"2019111716305794600_B17","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","article-title":"Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome positive acute lymphoblastic leukemia without additional chemotherapy: results of the GIMEMA LAL0201-B protocol","volume":"109","author":"Vignetti","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B18","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2007-02-073528","article-title":"Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study","volume":"110","author":"Ottmann","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/ng1343","article-title":"Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia","volume":"36","author":"Hu","year":"2004","journal-title":"Nat Genet"},{"key":"2019111716305794600_B20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"2019111716305794600_B21","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","article-title":"Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ ECOG2993","volume":"113","author":"Fielding","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B22","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1182\/blood-2008-10-184093","article-title":"Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation","volume":"113","author":"Bachanova","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B23","first-page":"600","article-title":"Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia","volume":"7","author":"Earl","year":"2009","journal-title":"Clin Adv Hematol Oncol"},{"key":"2019111716305794600_B24","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.leu.2405032","article-title":"High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis","volume":"22","author":"Patel","year":"2008","journal-title":"Leukemia"},{"key":"2019111716305794600_B25","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2009-08-231217","article-title":"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics and outcome from the large randomised prospective trial (UKALL XII\/ECOG 2993)","volume":"114","author":"Marks","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B26","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"2019111716305794600_B27","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2005-11-4666","article-title":"Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII\/ECOG E2993","volume":"108","author":"Lazarus","year":"2006","journal-title":"Blood"},{"key":"2019111716305794600_B28","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B29","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"key":"2019111716305794600_B30","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3109\/10428199709039047","article-title":"Treatment of relapsed acute lymphoblastic leukemia with fludarabine, cytosine arabinoside and G-CSF","volume":"25","author":"Montillo","year":"1997","journal-title":"Leuk Lymph"},{"key":"2019111716305794600_B31","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0145-2126(99)00148-4","article-title":"A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia","volume":"24","author":"Rosen","year":"2000","journal-title":"Leuk Res"},{"key":"2019111716305794600_B32","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/cncr.21932","article-title":"Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis","volume":"106","author":"Yanada","year":"2006","journal-title":"Cancer"},{"key":"2019111716305794600_B33","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/sj.leu.2404420","article-title":"Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)\/E2A-PBX1 and t(4;11)\/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study","volume":"20","author":"Vey","year":"2006","journal-title":"Leukemia"},{"key":"2019111716305794600_B34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.bbmt.2005.12.029","article-title":"A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission","volume":"12","author":"Marks","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111716305794600_B35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/sj.bmt.1705221","article-title":"Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation","volume":"37","author":"Dahlke","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2019111716305794600_B36","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.2009.008649","article-title":"Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission","volume":"94","author":"Patel","year":"2009","journal-title":"Haematologica"},{"key":"2019111716305794600_B37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.bmt.1705464","article-title":"Alternative donor transplants for adult acute lymphoblastic leukaemia: a comparison of the three major options","volume":"38","author":"Marks","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2019111716305794600_B38","first-page":"114","article-title":"Allogeneic hematopoietic cell transplantation can cure some patients with acute leukemia in relapse or primary induction failure: a CIBMTR Study [abstract 528]","author":"Duval","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3324\/haematol.11960","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation","volume":"93","author":"Mohty","year":"2008","journal-title":"Haematologica"},{"issue":"3","key":"2019111716305794600_B40","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","article-title":"The outcome of full intensity and reduced intensity conditioning matched sibling or unrelated donor (URD) transplantation in adults with Philadelphia chromosome negative acute lymphoblastic leukemia (PH- ALL) in first and second complete remission (CR1 and CR2)","volume":"116","author":"Marks","year":"2010","journal-title":"Blood"},{"key":"2019111716305794600_B41","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.leu.2404065","article-title":"Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials","volume":"20","author":"Dhedin","year":"2006","journal-title":"Leukemia"},{"key":"2019111716305794600_B42","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/asheducation-2005.1.131","article-title":"Acute lymphoblastic leukaemia: older patients and newer drugs","author":"Larson","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111716305794600_B43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2009-07-232124","article-title":"A population-based cytogenetic study of adults with acute lymphoblastic leukemia","volume":"115","author":"Moorman","year":"2010","journal-title":"Blood"},{"key":"2019111716305794600_B44","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"2019111716305794600_B45","first-page":"533","article-title":"Treatment of elderly patients with acute lymphoblastic leukemia","author":"Hoelzer","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111716305794600_B46","first-page":"1556","article-title":"A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB Study 9111","volume":"92","author":"Larson","year":"1998","journal-title":"Blood"},{"key":"2019111716305794600_B47","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"2019111716305794600_B48","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard risk acute lymphoblastic leukemia","volume":"107","author":"Bruggeman","year":"2006","journal-title":"Blood"},{"key":"2019111716305794600_B49","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1182\/blood-2006-07-037093","article-title":"Molecular relapse in standard risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06\/99 and 07\/03 trials","volume":"109","author":"Raff","year":"2007","journal-title":"Blood"},{"key":"2019111716305794600_B50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2009.07941.x","article-title":"Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993","volume":"148","author":"Patel","year":"2010","journal-title":"Br J Haematol"},{"key":"2019111716305794600_B51","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/nature05690","article-title":"Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia","volume":"446","author":"Mullighan","year":"2007","journal-title":"Nature"},{"key":"2019111716305794600_B52","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric inspired therapy in adults with Philadelphia chromosome negative acute lymphoblastic leukemia: the GRAALL 2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/13\/1493754\/bep00110000013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/13\/1493754\/bep00110000013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T16:31:19Z","timestamp":1574008279000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/13\/96415\/Treating-the-Older-Adult-With-Acute-Lymphoblastic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.13","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}